<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191486</url>
  </required_header>
  <id_info>
    <org_study_id>T817MAEU201</org_study_id>
    <secondary_id>2018-003567-66</secondary_id>
    <nct_id>NCT04191486</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD</brief_title>
  <official_title>A Phase 2 Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FUJIFILM Toyama Chemical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FUJIFILM Toyama Chemical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein
      phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with
      placebo in patients with a diagnosis of MCI due to AD or mild AD.

      Secondary objectives are:

        1. To evaluate in patients on T-817MA and placebo:

             -  cognitive function measured by the Clinical Dementia Rating Scale Sum of Boxes
                (CDR-sb) and working memory and attention domain as measured by the Cognitive
                Functional Composite (CFC).

             -  AD-related biomarkers in CSF and plasma

             -  imaging analysis using volumetric magnetic resonance imaging (vMRI)

             -  alpha/theta ratio of the electroencephalogram (EEG)

        2. To evaluate the safety of T-817MA by clinical laboratory tests and adverse events (AEs).

        3. To evaluate the pharmacokinetics of T-817MA
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in the CSF p-tau181 from Baseline to Week 78</measure>
    <time_frame>Baseline to Week 78</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the CSF p-tau181 from Baseline to Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the CSF p-tau217 from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the CSF total tau from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the CSF Aβ1-42 from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the CSF Aβ1-40 from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the CSF neurofilament light (NFL) from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the CSF neurogranin from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the CSF YKL-40 from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the CSF Aβ1-42/Aβ1-40 ratio from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the plasma Aβ1-42 from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the plasma Aβ1-40 from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the plasma NFL from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in cognitive function assessed by CDR-sb and working memory and attention domain as measured by the CFC from Baseline to Weeks 28, 52 and 78</measure>
    <time_frame>Baseline to Weeks 28, 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in brain volume (total brain volume (TBV), ventricular volume and hippocampal volume) and cortical thickness measured by vMRI from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in alpha/theta ratio measured by the EEG from Baseline to Weeks 52 and 78</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by the occurrence of AEs, clinical laboratory tests, vital signs, physical examinations, ECGs</measure>
    <time_frame>Screening to Week 82</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK analysis of T-817MA with assessment of maximum plasma concentration (Cmax)</measure>
    <time_frame>Weeks 16, 28, 40, and 65</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK analysis of T-817MA with assessment of minimum plasma concentration (Cmin)</measure>
    <time_frame>Weeks 16, 28, 40, and 65</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK analysis of T-817MA with assessment of total daily exposure (AUC0-24h)</measure>
    <time_frame>Weeks 16, 28, 40, and 65</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>T-817MA (448 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-817MA</intervention_name>
    <description>224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.</description>
    <arm_group_label>T-817MA (448 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Female of non-childbearing potential or male, ages 50 to 80 years (inclusive)

          -  MCI due to AD or mild AD per NIA-AA diagnostic criteria (Jack et al., 2018), with MMSE
             24 to 30 (inclusive)

          -  CSF results at Screening consistent with the presence of Aß and p-tau181 abnormality
             (≤1000 pg/ml for Aß, ≥19 pg/ml for p-tau181).

          -  Taking stable dose of AChE Inhibitor (donepezil, galantamine or rivastigmine) at least
             for 3 months prior to randomization, or not taking any AChE Inhibitors.

        Key Exclusion Criteria:

          -  MRI of the brain within the previous 2 years that showed pathology that would be
             inconsistent with a diagnosis of AD

          -  Taking memantine

          -  Any contraindications to lumbar puncture

          -  Any contraindications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>If male, patients must:
agree he will not donate sperm during the study and until 104 days after the last dose, AND
be required to use highly effective methods of contraception during the study and until 104 days after the last dose
If female, patients must:
be post-menopausal (i.e. no menses for 12 months without an alternative medical cause) OR
be permanently sterilized with methods including hysterectomy, bilateral salpingectomy and bilateral oophorectomy</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Scheltens, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VUmc Alzheimer Centrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Larah de Groot (for recruitment)</last_name>
    <phone>+31 30 656 9186</phone>
    <email>larah.degroot@juliusclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tomohiro Okuda (for drug information)</last_name>
    <email>fftc-clinicaltrial-info1@fujifilm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FNUSA - Mezinarodni centrum klinickeho vyzkumu</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A-shine, s.r.o.</name>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLINTRIAL, s.r.o.</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VESTRACLINICS, s.r.o.</name>
      <address>
        <city>Rychnov</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Psychosomatik und Psychotherapie Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg Institut für Kognitive Neurologie und Demenzforschung</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut für Studien zur Psychischen Gesundheit (ISPG)</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Klinik für Allgemeine Neurologie</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock Zentrum für Nervenheilkunde Klinik für Psychosomatik und Psychotherapeutische Medizin</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem KK, Pszichiátriai Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jávorszky Ödön Városi Kórház, Gyógyszertár</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem, Pszichiátriai és Pszichoterápiás Klinika</name>
      <address>
        <city>Győr</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Neurológiai Klinika Gyógyszertára, C földszint</name>
      <address>
        <city>Vác</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brain Research Center Den Bosch</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala ziekenhuis</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundació ACE</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAE Oroitu</name>
      <address>
        <city>Getxo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Victoria Eugenia - Cruz Roja</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Bath</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glasgow memory Clinic</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memory Assessment &amp; Research Centre</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larah de Groot</last_name>
      <phone>+31 30 656 9186</phone>
      <email>larah.degroot@juliusclinical.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Details for sharing data have not been decided yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

